199 related articles for article (PubMed ID: 25901742)
1. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
Reikvam H; Hoang TT; Bruserud Ø
Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.
Reikvam H; Hauge M; Brenner AK; Hatfield KJ; Bruserud Ø
Expert Rev Hematol; 2015 Jun; 8(3):299-313. PubMed ID: 25835070
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy of acute myeloid leukemia.
Carneiro BA; Altman JK; Kaplan JB; Ossenkoppele G; Swords R; Platanias LC; Giles FJ
Expert Rev Anticancer Ther; 2015 Apr; 15(4):399-413. PubMed ID: 25623136
[TBL] [Abstract][Full Text] [Related]
4. Novel drug targets in acute leukemia.
Stock W
Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
[No Abstract] [Full Text] [Related]
5. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
Dinner SN; Giles FJ; Altman JK
Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
Tsai CT; So CW
Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulators and their impact on therapy in acute myeloid leukemia.
Pastore F; Levine RL
Haematologica; 2016 Mar; 101(3):269-78. PubMed ID: 26928248
[TBL] [Abstract][Full Text] [Related]
10. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
11. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.
Gao C; Dimitrov T; Yong KJ; Tatetsu H; Jeong HW; Luo HR; Bradner JE; Tenen DG; Chai L
Blood; 2013 Feb; 121(8):1413-21. PubMed ID: 23287862
[TBL] [Abstract][Full Text] [Related]
12. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
13. Targeting epigenetic changes in acute myeloid leukemia.
Blum W; Marcucci G
Clin Adv Hematol Oncol; 2005 Nov; 3(11):855-65, 882. PubMed ID: 16491631
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation as a pathogenic event and as a therapeutic target in AML.
Schoofs T; Müller-Tidow C
Cancer Treat Rev; 2011; 37 Suppl 1():S13-8. PubMed ID: 21612874
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood.
Popova EY; Claxton DF; Lukasova E; Bird PI; Grigoryev SA
Exp Hematol; 2006 Apr; 34(4):453-62. PubMed ID: 16569592
[TBL] [Abstract][Full Text] [Related]
16. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
17. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
Wouters BJ; Delwel R
Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
